218 related articles for article (PubMed ID: 28559410)
1. Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma.
Bossart S; Thurneysen S; Rushing E; Frontzek K; Leske H; Mihic-Probst D; Nagel HW; Mangana J; Goldinger SM; Dummer R
Oncologist; 2017 Jun; 22(6):749-753. PubMed ID: 28559410
[TBL] [Abstract][Full Text] [Related]
2. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
[TBL] [Abstract][Full Text] [Related]
3. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
4. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.
Williams TJ; Benavides DR; Patrice KA; Dalmau JO; de Ávila AL; Le DT; Lipson EJ; Probasco JC; Mowry EM
JAMA Neurol; 2016 Aug; 73(8):928-33. PubMed ID: 27271951
[TBL] [Abstract][Full Text] [Related]
5. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
Ali AK; Watson DE
Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
[TBL] [Abstract][Full Text] [Related]
6. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.
Kirchberger MC; Hauschild A; Schuler G; Heinzerling L
Eur J Cancer; 2016 Sep; 65():182-4. PubMed ID: 27501507
[TBL] [Abstract][Full Text] [Related]
7. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
[TBL] [Abstract][Full Text] [Related]
8. Immune mediated neuropathy following checkpoint immunotherapy.
Gu Y; Menzies AM; Long GV; Fernando SL; Herkes G
J Clin Neurosci; 2017 Nov; 45():14-17. PubMed ID: 28765062
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy-induced hypothyroidism A report of melanoma treated by ipilimumab and nivolumab.
Haissagerre M; Prey S; Lauro C; Rousset M; Georges A; Corcuff JB
Ann Biol Clin (Paris); 2018 Jun; 76(3):326-328. PubMed ID: 29862971
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma.
Barone A; Hazarika M; Theoret MR; Mishra-Kalyani P; Chen H; He K; Sridhara R; Subramaniam S; Pfuma E; Wang Y; Li H; Zhao H; Zirkelbach JF; Keegan P; Pazdur R
Clin Cancer Res; 2017 Oct; 23(19):5661-5665. PubMed ID: 28179454
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
12. Acute visual loss after ipilimumab treatment for metastatic melanoma.
Wilson MA; Guld K; Galetta S; Walsh RD; Kharlip J; Tamhankar M; McGettigan S; Schuchter LM; Fecher LA
J Immunother Cancer; 2016; 4():66. PubMed ID: 27777775
[TBL] [Abstract][Full Text] [Related]
13. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
[No Abstract] [Full Text] [Related]
14. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.
Savoia P; Astrua C; Fava P
Hum Vaccin Immunother; 2016 May; 12(5):1092-101. PubMed ID: 26889818
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment.
Bir Yucel K; Sutcuoglu O; Yazıcı O; Yıldız Y; Şenol E; Uner A
J Oncol Pharm Pract; 2023 Apr; 29(3):760-763. PubMed ID: 35938177
[TBL] [Abstract][Full Text] [Related]
19. Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma.
Ranganath HA; Panella TJ
J Immunother; 2015 Jun; 38(5):211. PubMed ID: 25962109
[TBL] [Abstract][Full Text] [Related]
20. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
Changizzadeh PN; Mukkamalla SKR; Armenio VA
J Immunother Cancer; 2017 Dec; 5(1):97. PubMed ID: 29254501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]